MARKED UP VERSION OF AMENDED CLAIMS - OZ 49727

3. A process as claimed in claim 1 [any of the preceding claims], wherein the plastic mixture is shaped in a molding calender to dosage forms.

5. A solid dosage form which is essentially free of aliphatic C_2-C_8-di- and -tricarboxylic acids and aromatic C_6-C_{10}-monocarboxylic acids, obtainable by a process as claimed in claim 1 [any of claims 1 to 4].

CURRENT CLAIMS - OZ 49727

1. A process for producing solid dosage forms which are suitable for oral or rectal administration for humans and animals, wherein

   a) 0.5 to 30% by weight of at least one active ingredient,

   b) 0.5 to 70% by weight of at least one cyclodextrin,

   c) 10 to 98% by weight of at least one polymeric binder, selected from polyethylene glycol having a molecular weight above 1000, polyvinylpyrrolidone or copolymers comprising N-vinylpyrrolidone and vinyl acetate and

   d) 0 to 50% by weight of conventional excipients.

are mixed and plasticized at a temperature below 220°C without adding a solvent and the resulting plastic mixture is shaped to the dosage form.

2. A process as claimed in claim 1, wherein the molar ratio between active ingredient and cyclodextrin is in the range from 0.1 to 4.0.

3. A process as claimed in claim 1, wherein the plastic mixture is shaped in a molding calender to dosage forms.

4. A process as claimed in claim 3, wherein a molding calender with counterrotating molding rolls is used, with at least one of the molding rolls having on its surface depressions to receive and shape the plastic mixture.

5. A solid dosage form which is essentially free of aliphatic C_2-C_8-di- and -tricarboxylic acids and aromatic C_6-C_{10}-monocarboxylic acids, obtainable by a process as claimed in claim 1.

6. A solid dosage form as claimed in claim 5, wherein at least 10% by weight of the active ingredient are present in the form of a cyclodextrin/active ingredient complex.